antisense

Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Fierce Biotech
Wave Life Sciences
antisense
WVE-004
clinical trials
ALS
dementia
Flag link:
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen
Flag link:
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
Clinical Trials Arena
GSK
bepirovirsen
hepatitis B
antisense
Flag link:
GSK hepatitis B hope bepirovirsen heads for phase 3 test
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Pharmaforum
GSK
hepatitis B
clinical trials
antisense
bepirovirsen
Flag link:
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect
Fierce Biotech
Biogen
Ionis Pharmaceuticals
ALS
clinical trials
antisense
SOD1-ALS
Flag link:
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
Fierce Biotech
Ultragenyx
GeneTx Biotherapeutics
Angelman Syndrome
clinical trials
antisense
GTX-102
Flag link:
Biogen brings in a successor to Spinraza
Biogen brings in a successor to Spinraza
BioPharma Dive
Biogen
Ionis Pharmaceuticals
Spinraza
BIIB115
antisense
spinal muscular atrophy
Flag link:
AstraZeneca, Ionis close deal on antisense therapy development
AstraZeneca, Ionis close deal on antisense therapy development
Pharmaceutical Business Review
AstraZeneca
Ionis Pharmaceuticals
antisense
eplontersen
Flag link:
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Fierce Biotech
Pfizer
Regeneron
antisense
clinical trials
vupanorsen
dyslipidemia
Flag link:
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
Endpoints
Ionis Pharmaceuticals
antisense
Flamingo Therapeutics
RNA
Flag link:
Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial
Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial
Fierce Biotech
Cardior
antisense
heart failure
Bristol Myers Squibb
funding
Flag link:
Ultragenyx pauses antisense trial after patients lose ability to walk
Ultragenyx pauses antisense trial after patients lose ability to walk
Fierce Biotech
Ultragenyx
clinical trials
GTX-102
antisense
Flag link:
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
Pharmaforum
GSK
antisense
hepatitis B
clinical trials
GSK3228836
Ionis Pharmaceuticals
Flag link:
Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals
Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals
Endpoints
Novartis
Akcea
Medco
AKCEA-APOCIII-LRx
antisense
Flag link:
GSK licenses Ionis' midphase hepatitis B program for $25M
GSK licenses Ionis' midphase hepatitis B program for $25M
Fierce Biotech
GSK
Ionis Pharmaceuticals
antisense
hepatitis B
Flag link:
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
BioSpace
Biogen
tofersen
antisense
Ionis Pharmaceuticals
ALS
Flag link:
Audentes to develop vectorized antisense therapies with Nationwide
Audentes to develop vectorized antisense therapies with Nationwide
BioCentury
Audentes Therapeutics
antisense
Flag link:
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
type 2 diabetes
antisense
Flag link:
Roche gets option to Ionis' antisense dry AMD candidate
Roche gets option to Ionis' antisense dry AMD candidate
BioCentury
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
antisense
dry age-related macular degeneration
Flag link:
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
CP Wire
PureTech
Roche
drug development
antisense
Flag link:

Pages